Cutter Capital Management LP Has $12.32 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Cutter Capital Management LP increased its holdings in Teva Pharmaceutical Industries by 37.1%, owning approximately 801,806 shares, which makes up about 5.4% of its portfolio.
• Teva reported $0.66 earnings per share (EPS) for the last quarter, beating analysts' expectations of $0.64, despite revenue falling slightly short of estimates.
• Analysts have rated Teva stock as a buy, with target prices ranging from $22.00 to $25.00, reflecting a positive outlook for the company moving forward.

Cutter Capital Management LP lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 37.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 801,806 shares of the company's stock after purchasing an additional 216,923 shares during the period. Teva Pharmaceutical Industries accounts for approximately 5.4% of Cutter Capital Management LP's investment portfolio, making the stock its 10th biggest holding. Cutter Capital Management LP owned approximately 0.07% of Teva Pharmaceutical Industries worth $12,324,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. US Bancorp DE boosted its holdings in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after purchasing an additional 656 shares in the last quarter. Bfsg LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares in the last quarter. Factorial Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 0.3% in the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock valued at $5,118,000 after purchasing an additional 1,000 shares in the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after purchasing an additional 1,033 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 4.1% in the 4th quarter. Mackenzie Financial Corp now owns 29,889 shares of the company's stock valued at $659,000 after purchasing an additional 1,171 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of a number of research analyst reports. UBS Group reduced their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.71.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.46 during mid-day trading on Friday, hitting $18.94. 7,802,703 shares of the stock traded hands, compared to its average volume of 9,725,214. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a market cap of $21.72 billion, a PE ratio of -118.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.72. The firm has a 50 day simple moving average of $17.04 and a two-hundred day simple moving average of $16.40.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's quarterly revenue was up .3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.